Beyond the gold rush

Beyond the gold rush

Before we get into the Lilly earnings results a few items of interest.

1. “Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, announced that Eversense® has been granted an integrated CGM (iCGM) designation by the US Food and Drug Administration (FDA). “

That’s very nice but it won’t help much.

2. “Wrocław, Poland-based Biotts, a biopharmaceutical company and global pioneer in Transdermal Drug Delivery (through . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.